(Q57700334)

English

D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis

article

In more languages

Statements

scholarly article

0 references

0 references

D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis (English)

0 references

0 references

Déborah Ducasse

object named as

Deborah Ducasse

1

0 references

object named as

Guillaume Fond

10

0 references

Jean-Arthur Micoulaud-Franchi

object named as

Jean-Arthur Micoulaud-Franchi

6

0 references

object named as

Marion Leboyer

9

0 references

author name string

Laurent Boyer

2

0 references

Pierre Michel

3

0 references

Anderson Loundou

4

0 references

Alexandra Macgregor

5

0 references

Philippe Courtet

7

0 references

Mocrane Abbar

8

0 references

publication date

6 March 2014

0 references

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

0 references

231

0 references

18

0 references

3765-3770

0 references

https://scigraph.springernature.com/pub.10.1007/s00213-014-3516-3

0 references

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Grand challenges in global mental health: integration in research, policy, and practice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Dopamine and serotonin receptor binding and antipsychotic efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-014-3516-3

21 January 2018

Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and incidence studies of anxiety disorders: a systematic review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence-based pharmacotherapy of obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/24599398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-014-3516-3

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57700334&oldid=1841266884"